TRSZX Performance — T. Rowe Price Mid-Cap Index Fund, Z Class
Data updated: 2026-08-27
TRSZX returned +14.74% year to date and +22.44% over one year to Jun 2026. Annualised returns are +20.41% over 3 years and +7.31% over 5 years. The fund beat its US Mid-Cap Blend category average: $100 invested three years ago grew to $175, against $150 for the category, and to $122 over one year, against $122. Volatility over the past three years was 17.68% a year. In the 12 months to Jun 2026 the fund took in a net $149.2M, and assets reached $503.33M.
TRSZX Growth of $100
What $100 invested in T. Rowe Price Mid-Cap Index Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Mid-Cap Blend category average over the same months.
| Period | TRSZX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $122 | $122 |
| 3 years (Jul 2023 – Jun 2026) | $175 | $150 |
| 5 years (Jul 2021 – Jun 2026) | $142 | $147 |
| Since data start (Mar 2020 – Jun 2026) | $338 | $214 |
TRSZX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +14.74% |
| 1 year | +22.44% |
| 3 years (annualised) | +20.41% |
| 5 years (annualised) | +7.31% |
TRSZX Annual Returns
Calendar-year total returns of T. Rowe Price Mid-Cap Index Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +14.74% |
| 2025 | +12.74% |
| 2024 | +20.11% |
| 2023 | +30.10% |
| 2022 | −28.48% |
| 2021 | +11.00% |
| 2020 (Mar–Dec) | +110.72% |
TRSZX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.7% | +1.8% | −4.8% | +7.5% | +4.4% | +4.8% | — | — | — | — | — | — |
| 2025 | +6.7% | −5.9% | −8.1% | +0.5% | +8.1% | +5.5% | +2.4% | +3.0% | +1.8% | +0.5% | −0.5% | −0.5% |
| 2024 | −1.4% | +6.6% | +3.1% | −6.1% | +2.3% | +0.6% | +3.8% | +1.6% | +2.1% | +1.8% | +12.1% | −6.6% |
| 2023 | +11.3% | −1.5% | −1.5% | −2.4% | +1.5% | +8.3% | +5.7% | −3.5% | −4.2% | −5.8% | +11.8% | +9.2% |
| 2022 | −9.7% | −0.7% | +0.5% | −10.8% | −2.9% | −9.6% | +10.5% | −2.0% | −9.9% | +6.8% | +4.1% | −6.5% |
| 2021 | +0.6% | +4.3% | −0.9% | +5.6% | −1.0% | +3.9% | +0.1% | +1.8% | −4.2% | +6.6% | −5.9% | +0.5% |
| 2020 | — | — | +10.2% | +16.9% | +10.2% | +4.2% | +7.5% | +8.6% | −2.4% | −0.6% | +18.0% | +6.7% |
TRSZX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 17.68%
- 3-year Sharpe ratio: 0.90 (vs 4.5% risk-free rate)
- Best month: +12.06% (Nov 2024)
- Worst month: −8.12% (Mar 2025)
TRSZX Fund Flows
Monthly money in and out of T. Rowe Price Mid-Cap Index Fund, from SEC Form N-PORT.
- 12-month net flow: $149.2M
- 12-month gross sales (incl. reinvestments): $200.2M
- Sales ÷ redemptions: 3.92×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $9.6M | $5.3M | $4.4M |
| May 2026 | $53.2M | $4.0M | $49.2M |
| Apr 2026 | $6.3M | $1.6M | $4.7M |
| Mar 2026 | $5.4M | $1.3M | $4.1M |
| Feb 2026 | $17.1M | $783K | $16.3M |
| Jan 2026 | $23.5M | $9.9M | $13.6M |
| Dec 2025 | $41.5M | $6.6M | $34.8M |
| Nov 2025 | $8.3M | $3.3M | $5.0M |
| Oct 2025 | $8.7M | $3.5M | $5.3M |
| Sep 2025 | $11.6M | $9.8M | $1.8M |
| Aug 2025 | $5.7M | $1.8M | $3.9M |
| Jul 2025 | $9.4M | $3.1M | $6.3M |
TRSZX Assets Under Management
Net assets of T. Rowe Price Mid-Cap Index Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $503.33M |
| 2026-03-31 | $373.51M |
| 2025-12-31 | $349.58M |
| 2025-09-30 | $327.66M |
| 2025-06-30 | $293.80M |
| 2025-03-31 | $245.13M |
| 2024-12-31 | $234.71M |
| 2024-09-30 | $204.53M |
| 2024-06-30 | $180.27M |
| 2024-03-31 | $179.78M |
| 2023-12-31 | $151.88M |
| 2023-09-30 | $127.37M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.